The NHS is set to revolutionise the way it brings pioneering new treatments to patients, with a series of pilot programmes aimed at speeding up access to innovative medicines. These initiatives, developed by a joint taskforce of government officials, pharmaceutical industry representatives, and NHS stakeholders, have been months in the making – literally. The pilots are a direct outcome of a 10-week 'sprint' process that also incorporated input from patient organisations.
Starting as early as September, these programmes will explore novel approaches to medicines pricing, patient access, and the adoption of new therapies. A key focus will be on accelerating the availability of innovative treatments that have already met rigorous safety, quality, and clinical standards, particularly those for rare conditions where treatment options are often limited.
This announcement follows significant adjustments made to the National Institute for Health and Care Excellence (NICE)'s cost-effectiveness threshold in April 2023. These changes have already resulted in the approval of nine additional medicines for NHS patients across England and Wales. These newly approved treatments address a range of serious and life-limiting conditions, including various blood disorders, autoimmune diseases, and several forms of cancer.
The Health and Social Care Secretary, James Murray, highlighted the importance of timely access to new medicines, stating that "When a new medicine is proven to work, patients shouldn’t have to wait." He emphasised that these pilots are designed to deliver life-changing treatments to NHS patients more rapidly and equitably, while ensuring value for taxpayers.
NICE anticipates that, as these new mechanisms become fully operational, up to five additional medicines could be approved annually compared to previous arrangements. This would enhance its track record of approving over 90% of assessed medicines. The pilots also include a new method to account for the broader societal benefits of new medicines and dedicated regional funding will be introduced to improve patient access to priority medicines.
These initial pilots underpin the government's commitment, outlined in the US-UK pharmaceutical arrangement, to double spending on innovative medicines from 0.3% to 0.6% of GDP over the next decade. This strategic investment aims to bolster the UK's position as a global leader in life sciences and foster research.